LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
BCIQ Data Coverage
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
3rd Biotech CEO & Investor Reception
East-West Biopharma Summit 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Macrogen Inc.
Headquarters:
Seoul, South Korea
Website:
http://www.macrogen.co.kr
Year Founded:
1997
Status:
Public
Industry Sector:
HealthServices
CEO:
Chang-Hoon Kim, PhD; Jeong-Sun Seo, PhD
Number Of Employees:
529
Enterprise Value:
$148,756,225
PE Ratio:
-25.39
Exchange/Ticker 1:
KOSDAQ:038290
Exchange/Ticker 2:
N/A
Latest Market Cap:
$119,743,647
BioCentury
|
Nov 18, 2022
Regulation
Nov. 17 Quick Takes: FDA approves Provention’s mAb to slow onset of diabetes
Plus: Rezo’s launch, deals by Regeneron-CytomX and Marinus-Tenacia, the end of a GSK-Immatics deal, and Tenaya’s funding
Read More
BioCentury
|
Oct 18, 2022
Deals
Oct. 17 Quick Takes: Gilead, MacroGenics in deal for bispecific
Biogen’s ALS candidate delayed, plus updates from Oculis, Treeline, Minerva, Acrivon and more
Read More
BioCentury
|
Dec 7, 2018
Tools & Techniques
Germline editing gets technical
Why there’s a gap in standards research for somatic cell versus germline editing
Read More
BioCentury
|
Apr 28, 2016
Finance
Public-Private Partnership Roundup
Highlights of public-private partnerships from 1Q16
Read More
BioCentury
|
Feb 13, 2016
Company News
GenomeAsia 100K launches Asian sequencing initiative
Read More
BioCentury
|
Jan 20, 2014
Company News
Illumina sales and marketing update
Read More
BioCentury
|
Jan 15, 2014
Company News
Illumina introduces $1,000 human genome system
Read More
BioCentury
|
Mar 1, 2012
Cover Story
REThinking lung cancer
Read More
BioCentury
|
Aug 2, 2010
Company News
Illumina sales and marketing update
Read More
BioCentury
|
Jul 9, 2001
Company News
Macrogen Inc. other research news
Read More
Items per page:
10
1 - 10 of 10
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help